Marksans Pharma’s wholly owned subsidiary -- Relonchem has received Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.
Earlier, Relonchem had received marketing authorization for the product Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.
Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.
